Results 31 to 40 of about 15,404 (212)

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)

Endocrine Connections, 2017
Objective: To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study).
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, Sunitha Jothydev   +4 more
doaj   +1 more source

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundTo evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period.MethodsOur study design involved the addition of 100 mg sitagliptin once ...
Hye Soo Chung, Moon-Kyu Lee
doaj   +1 more source

Sitagliptin and other ‘gliptins’ - why prescribe them?

, 2016
Introduction\ud \ud In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors (‘gliptins’).
Dimmitt, Simon B., Doggrell, Sheila
core   +1 more source

Sex‐Specific Regulation of Glycemic Homeostasis by Theabrownin from Pu‐erh Tea

Advanced Science, EarlyView.
Pu‐erh tea's key component, theabrownin (TB), lowers blood glucose in a sex‐specific manner. In females, estrogen boosts intestinal MUC2 production, which dramatically enhances TB's ability to inhibit the carbohydrate‐digesting enzyme α‐glucosidase.
Yang Li, Junliang Kuang, Dan Zheng, Jieyi Wang, Kun Ge, Chun Qu, Xiaojiao Zheng, Zhenxing Ren, Fengjie Huang, Mingliang Zhao, Yimin Sun, Huiheng Zhang, Keke Ding, Xixi Xia, Yajun Tang, Lu Liu, Jian Zhou, Fei Gao, Xiaohui Ma, Yongquan Xu, Guoxiang Xie, Aihua Zhao, Wei Jia   +22 more
wiley   +1 more source

Analysis of published and unpublished sitagliptin (Januvia) studies in humans

, 2014
August 25, 2014 5 pm Bogotá time zone Sitagliptin (Januvia) ClinicalTrials.gov records completed before Jan 2011. Total number of records = 115Expert search terms (PubMed): http://goo.gl/pIdDaQ Records not found = 85Results = 40 Expert search terms of ...
Jorge H Ramirez (587826)
core   +1 more source

Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

PLoS ONE, 2013
BackgroundThe effect of metformin, pioglitazone and sitagliptin on β-cell function in the treatment of type 2 diabetes is controversial. Therefore, we performed a systematic review and meta-analysis to obtain a better understanding in the β-cell effects ...
Jin Lu, Jiajie Zang, Huihua Li
doaj   +1 more source

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Cancer Medicine, 2020
Sitagliptin is an emerging oral hypoglycemic agent that inhibits the development of a wide variety of tumors. Current researches indicate that the abnormal activation of Yes‐associated protein (YAP) promotes the proliferation and poor prognosis of ...
Qi Wang, Pan Lu, Tao Wang, Qianqian Zheng, Yan Li, Sean X. Leng, Xin Meng, Biao Wang, Jisheng Xie, Haiyan Zhang   +9 more
doaj   +1 more source

A Strong Lewis Acidic Diethylsilylium Catalyst for Direct Sulfonamidation of Challenging Ketones

Advanced Science, EarlyView.
Low‐substitution‐order silylium ions (R2HSi+) exhibit exceptional Lewis acidic activity. We report diethylsilylium‐catalyzed reductive sulfonamidation of functionalized ketones to access β‐amino esters. The in situ generated ion pair shows enhanced reactivity, with diethylsilane serving as both reductant and precatalyst. The developed protocol proceeds
Woo Hee Kim, Muhammad Israr, You Kyoung Chung, Shinwon Ham, Joonsuk Huh, Han Yong Bae   +5 more
wiley   +1 more source

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice

International Journal of Endocrinology, 2018
Obesity and type 2 diabetes are the most common metabolic diseases globally. They are associated with inflammation, oxidative stress, autophagy, and insulin resistance.
Wenbin Zheng, Jing Zhou, Shasha Song, Wen Kong, Wenfang Xia, Lulu Chen, Tianshu Zeng   +6 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source